BIOCRYST PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $56.15 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-26
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $56.15M.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$18.26M.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$47.51M.
- BIOCRYST PHARMACEUTICALS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$51.32M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $56.15M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$18.26M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$47.51M 10-K · filed 2026-02-26 | -$47.33M 10-K · filed 2024-02-27 |
| 2022-12-31 | -$51.32M 10-K · filed 2025-02-25 | |
| 2021-12-31 | -$38.17M 10-K · filed 2024-02-27 | |
| 2020-12-31 | -$38.39M 10-K · filed 2023-02-27 | |
| 2019-12-31 | -$22.87M 10-K · filed 2022-02-28 | |
| 2018-12-31 | -$21.26M 10-K · filed 2021-03-01 | |
| 2017-12-31 | -$23.02M 10-K · filed 2020-03-13 | |
| 2016-12-31 | -$19.30M 10-K · filed 2019-03-14 | |
| 2015-12-31 | -$15.06M 10-K · filed 2018-03-12 | |
| 2014-12-31 | -$15.82M 10-K · filed 2017-02-27 | |
| 2013-12-31 | -$10.54M 10-K · filed 2016-02-26 | |
| 2012-12-31 | -$13.68M 10-K · filed 2015-03-02 | |
| 2011-12-31 | -$19.93M 10-K · filed 2014-03-10 | |
| 2010-12-31 | -$11.46M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |